Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Pharmaceutical Care Management ... today outlined policy solutions that could reduce prescription fraud ... Hill briefing, " Prescription Opioid Abuse: Fighting Back on ... Reform and PCMA. The briefing featured ... prescription drug abuse and fraud. The Centers for Disease ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... Summary GlobalData,s new report, "EU5 Esophagoscopes ... market data on the EU5 Esophagoscopes & Gastroscopes ... US dollars, volume (in units) and average prices ... Video Esophagoscopes, Flexible Non-Video (Fibre) Gastroscopes and Flexible ...
(Date:9/29/2014)... BEIJING , Sept. 29, 2014  Following US and ... accelerator, the China Food and Drug Administration (CFDA) has ... in the country. According to the International ... people are diagnosed with cancer every year in ... types including lung, gastric, colorectal, liver and esophageal cancers ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 3Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 2Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 3
... DIEGO, Dec. 18 Ambrx Inc. today announced ... with Merck & Co. Inc. to,develop a novel ... Factor 21 (FGF-21) for the treatment of type ... The collaboration utilizes Ambrx,s proprietary protein technology,ReCODE(TM), ...
... Epeius Biotechnologies,Corporation announced today that the company ... Rexin-G(R) from the Philippine Bureau of Food ... lead product as a safe,and effective treatment ... as a tumor-targeted anticancer agent, that actively ...
Cached Medicine Technology:Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc. 2ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 2ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 3
(Date:9/30/2014)... DC (PRWEB) September 30, ... **MEDIA ADVISORY** , From:        Hope ... Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Hope® Celebration , Date:        Thursday, ... Address:    The Army and Navy ...
(Date:9/30/2014)... Barbara Williamson shares her life story for the ... Life: Love, Sex and Commitment" . As co-founder with ... highly successful and controversial Sandstone Retreat in Malibu, California, ... started what became known as the hub of the ... outrageously popular, with a membership reaching 500 and nearly ...
(Date:9/30/2014)... 2014 Computer Resources of America, ... based in New York City, has been awarded ... to transform, manage, and support the IT environment ... a leading provider of innovative services that enable ... The contract will cover the four NY-metro ...
(Date:9/30/2014)... September 30, 2014 Bibliomotion is ... Redefining Leadership for the Complex Social Age by ... 2014). , In the book, the authors apply their leadership ... which to view the conversations, actions, and behaviors that leaders ... world. Click here to read a review of ...
(Date:9/30/2014)... 2014 RBS Reputation Management is reported to ... Your Name’. , The service name may surprise as ... the service this odd name, a management professional said, “This ... this name. We have named the service ‘Remove Your Name’ ... get rid of all those posts which light their name ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 3Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6Health News:RBS Reputation Management Announces A New Service ‘Remove Your Name’ 2
... virus should be monitored for high blood pressure, expert ... Adults with the skin disease shingles appear to be ... the area around the eyes, researchers report. , Previous ... exact frequency and risk for these phenomena are still ...
... types of human papillomavirus (HPV), a sexually transmitted virus, ... Current guidelines prioritize HPV vaccination of pre-adolescent girls, which ... but the value of vaccinating boys in the United ... School of Public Health (HSPH) researchers found that if ...
... Study finds two-thirds of those with the mysterious illness infected ... About two-thirds of patients with chronic fatigue syndrome sampled in ... , The finding, albeit preliminary, has raised hopes that there ... thus, down the line, treatments for the disease. , "This ...
... Reportlinker.com announces that a new market research report ... Reportlinker Adds Germany Wound Care Management Market Analysis ... http://www.reportlinker.com/p0151443/Reportlinker-Adds-Germany-Wound-Care-Management-Market-Analysis-and-Forecasts-to-2015.html , ... Analysis and Forecasts to 2015 report provides key ...
... Biomonitoring Study Detects Four Chemicals from EPA,s Recently-Announced Top ... Physicians for Social Responsibility (PSR), American Nurses Association (ANA) ... Chemicals In Health Care," the first investigation of ... , Today,s announcement was made on a national teleconference ...
... cause of death worldwide. Our evolutionary struggle with this ... UC Riverside. Population geneticist Leonard Nunney will ... Struggle With Cancer," at 7 p.m., Thursday, Oct. 15, in ... p.m. Seating is open. "Cancer is unlike other diseases," ...
Cached Medicine News:Health News:Shingles Raises Stroke Risk: Study 2Health News:Shingles Raises Stroke Risk: Study 3Health News:Vaccinating boys against human papillomavirus not cost-effective 2Health News:Vaccinating boys against human papillomavirus not cost-effective 3Health News:Retrovirus May Be at Root of Chronic Fatigue Syndrome 2Health News:Retrovirus May Be at Root of Chronic Fatigue Syndrome 3Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 2Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 3Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 4Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 5Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 6Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 7Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 8Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 9Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 10Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 11Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 12Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 13Health News:Reportlinker Adds Germany Wound Care Management Market Analysis and Forecasts to 2015 14Health News:Toxic Chemicals Found in Doctors and Nurses 2Health News:Evolutionary struggle with cancer is focus of public lecture at UC Riverside 2
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used to introduce large devices for vascular intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: